Your browser doesn't support javascript.
loading
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016.
Adusumilli, Prasad S; Cha, Edward; Cornfeld, Mark; Davis, Thomas; Diab, Adi; Dubensky, Thomas W; Evans, Elizabeth; Grogan, Jane L; Irving, Bryan A; Leidner, Rom S; Olwill, Shane A; Soon-Shiong, Patrick; Triebel, Frederic; Tuck, David; Bot, Adrian; Dansey, Roger D; Drake, Charles G; Freeman, Gordon J; Ibrahim, Ramy; Patel, Salil; Chen, Daniel S.
Afiliación
  • Adusumilli PS; Center for Cell Engineering; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065 USA.
  • Cha E; Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.
  • Cornfeld M; Idera Pharmaceuticals, 505 Eagleview Blvd, Ste 212, Exton, PA 19341 USA.
  • Davis T; Celldex Therapeutics, Inc, 119 Fourth Avenue, Needham, MA 02494 USA.
  • Diab A; University of Texas MD Anderson Cancer Center, 1515 Holcomb Blvd, Unit 430, Houston, TX 77030 USA.
  • Dubensky TW; Aduro Biotech, Inc, 740 Heinz Avenue, Berkeley, CA 94710 USA.
  • Evans E; Vaccinex, 1895 Mount Hope Avenue, Rochester, NY 14620 USA.
  • Grogan JL; Genentech, 1 DNA Way, 13-2079, South San Francisco, CA 94080 USA.
  • Irving BA; Cytomx Therapeutics, 151 Oyster Point Blvd, South San Francisco, CA 94080 USA.
  • Leidner RS; Earle A. Chiles Research Institute, Providence Cancer Center, 4805 NE Glisan St, Suite 2N35, Portland, OR 97213 USA.
  • Olwill SA; Pieris Pharmaceuticals GmbH, Lise-Meitner-Str 30, Freising, 85354 Germany.
  • Soon-Shiong P; NantKwest, Inc, 9920 Jefferson Blvd, Culver City, CA 90232 USA.
  • Triebel F; Immutep S.A.S., Parc Club Orsay, 2 Rue Jean Rostand, Orsay, 91893 France.
  • Tuck D; Curis, 4 Maguire Road, Lexington, MA 02421 USA.
  • Bot A; Kite Pharma, Inc, 2225 Colorado Ave, Santa Monica, CA 90404 USA.
  • Dansey RD; Merck & Co., Inc, 126 E. Lincoln Avenue, RY34-B270, Rahway, NJ 07065 USA.
  • Drake CG; Division of Hematology/Oncology, Columbia University Medical Center, 177 Fort Washington Avenue, Suite 6GN-435, 10032 New York, NY USA.
  • Freeman GJ; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 USA.
  • Ibrahim R; Parker Institute for Cancer Immunotherapy, 1 Letterman Drive, Suite D3500, San Francisco, CA 94129 USA.
  • Patel S; Bristol-Myers Squibb, 3401 Princeton Pike, Lawrenceville, NJ 08648 USA.
  • Chen DS; Genentech/Roche, 1 DNA Way, South San Francisco, CA 94080 USA.
J Immunother Cancer ; 5: 50, 2017.
Article en En | MEDLINE | ID: mdl-28649381
This report is a summary of 'New Cancer Immunotherapy Agents in Development' program, which took place in association with the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), on November 9, 2016 in National Harbor, Maryland. Presenters gave brief overviews of emerging clinical and pre-clinical immune-based agents and combinations, before participating in an extended panel discussion with multidisciplinary leaders, including members of the FDA, leading academic institutions and industrial drug developers, to consider topics relevant to the future of cancer immunotherapy.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra el Cáncer / Microambiente Tumoral / Inmunoterapia / Neoplasias Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: J Immunother Cancer Año: 2017 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra el Cáncer / Microambiente Tumoral / Inmunoterapia / Neoplasias Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: J Immunother Cancer Año: 2017 Tipo del documento: Article Pais de publicación: Reino Unido